↓ Skip to main content

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Overview of attention for article published in Clinical Cancer Research, January 2024
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
2 news outlets
twitter
6 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Published in
Clinical Cancer Research, January 2024
DOI 10.1158/1078-0432.ccr-23-3053
Pubmed ID
Authors

Daniel H. Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A. Subramanian, Peter J.P. Croucher, Tod Smeal, Fairooz F. Kabbinavar, Heinz-Josef Lenz

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 20%
Researcher 1 20%
Unknown 3 60%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 40%
Unknown 3 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2024.
All research outputs
#1,817,490
of 25,962,638 outputs
Outputs from Clinical Cancer Research
#1,335
of 13,361 outputs
Outputs of similar age
#28,151
of 360,062 outputs
Outputs of similar age from Clinical Cancer Research
#14
of 106 outputs
Altmetric has tracked 25,962,638 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,361 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 360,062 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.